
News|Articles|February 28, 2025
Executive Summary: Leveraging the Evolving Bioequivalence Regulatory Landscape to Enhance Inhaled Product Design and Development
Author(s)Vectura Group plc, Vectura
The regulatory landscape for bioequivalence continues to evolve, leveraging a broader suite of characterization techniques. These not only provide deeper product understanding, but also utility for generic product development as the potential for replacement of costly clinical studies becomes more of a reality.
Trending on Pharmaceutical Technology
1
What Jideytro's Approval Means for Drug Developers
2
Q&A : Brent Wilhelm on Supply Chains and Historical Demand Data
3
PharmTech Weekly Roundup—July 24, 2026
4
Midyear 2026 Check-In: AI Investment Skipped Pharma's Costliest Operational Problem
5